Clinical Trials

Adenocarcinoma, Stomach Neoplasms

NCT03013218 2025-08-01

A Study of Evorpacept (ALX148) in Patients With Advanced Solid Tumors and Lymphoma (ASPEN-01)

174 enrolled

Lymphoid

Lymphoma, Non-Hodgkin, Neoplasm Metastasis, Neoplasms

NCT04394624 2025-06-06

CARMEN-LC04

Phase 2 Terminated

31 enrolled 22 charts

Non-small Cell Lung Cancer Metastatic

NCT05311176 2025-05-11

nextHERIZON

Phase 2 Terminated

7 enrolled 8 charts

Stomach Neoplasms

NCT05062980 2025-02-20

Acclaim-2

Phase 1/2 Terminated

5 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04499924 2025-01-22

MOUNTAINEER-02

Phase 2/3 Completed

17 enrolled 23 charts

Adenocarcinoma Of Esophagus

NCT02065765 2025-01-09

International Expanded Access Program to Provide Ramucirumab for the Treatment of Metastatic Gastric Cancer

Approved for marketing

Stomach Neoplasms

NCT02307812 2025-01-09

Ramucirumab Use in Combination With Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcinoma; Temporary Authorization for Use (ATU) in France

Approved for marketing

Stomach Neoplasms

NCT02791334 2024-09-27

PACT

BreastDermatologicGastrointestinal

164 enrolled

Breast Neoplasms, Melanoma, Pancreatic Neoplasms

NCT04999761 2024-09-25

AB122 Platform Study

Phase 1 Recruiting

917 enrolled

GastrointestinalHead & NeckSarcomaThoracic

Biliary Tract Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Head and Neck Neoplasms, Neoplasm Metastasis, Stomach Neoplasms, Colorectal Neoplasms, Sarcoma, Alveolar Soft Part

NCT06542731 2024-08-07

An Open-label, Uncontrolled Study of ONO-4578 and ONO-4538 in Combination With Standard-of-care Docetaxel and Ramucirumab as Second-line Therapy in Patients With Advanced or Recurrent Non-small Cell Lung Cancer

Phase 1 Active not recruiting

42 enrolled

Carcinoma, Non-Small-Cell Lung

NCT02443324 2024-07-31

A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer

GastrointestinalGenitourinaryThoracic

175 enrolled 23 charts

Biliary Tract Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms

NCT02789345 2024-02-05

A Study of Ramucirumab (LY3009806) or Necitumumab (LY3012211) Plus Osimertinib in Participants With Lung Cancer

29 enrolled 16 charts

Carcinoma, Non-Small-Cell Lung

NCT06123494 2024-01-16

SHR-A1811 for Subjects With Her2-positive Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on or After First-line Anti-HER2 Therapy-containing Regimen

Phase 3 Recruiting

360 enrolled

HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

NCT04151563 2023-12-19

CheckMate 79X

Phase 1/2 Withdrawn

Carcinoma, Carcinoma, Non-Small-Cell Lung

NCT04145700 2023-09-13

CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Synovial Sarcoma

Phase 1/2 Terminated

23 enrolled 15 charts

Sarcoma

Sarcoma, Sarcoma, Synovial

NCT02426125 2023-08-21

RANGE

530 enrolled 22 charts

Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Urethral Neoplasms

NCT05800418 2023-04-05

Clinical Study to Compare the Pharmacokinetics and Safety of Ramucirumab Injection With Cyramza ® in Healthy Male Volunteers

88 enrolled

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Stomach Neoplasms

NCT04557384 2023-02-27

A Study of Ramucirumab (LY3009806) Given by Injection Under the Skin in Participants With Advanced Cancer

Phase 1 Terminated

3 enrolled 9 charts

Other solid neoplasm

Advanced Solid Tumor

NCT02435433 2023-01-20

REACH-2

399 enrolled 22 charts 2 FDA

Phase 2 Active not recruiting

Carcinoma, Hepatocellular, Liver Neoplasms

NCT05190445 2022-09-08

Cinrebafusp Alfa in Combination With Ramucirumab and Paclitaxel in HER2-High Gastric or GEJ Adenocarcinoma and in Combination With Tucatinib in HER2-Low Gastric or GEJ Andenocarinoma

80 enrolled

HER2-positive Gastric Cancer

NCT02898077 2022-06-14

A Study of Paclitaxel With or Without Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Cancer

440 enrolled 19 charts

Gastroesophageal Junction Adenocarcinoma

NCT01515306 2022-03-08

A Study of Ramucirumab (IMC-1121B) and Paclitaxel in Participants With Solid Tumors

Phase 2 Completed

48 enrolled 17 charts

Other solid neoplasm

Malignant Solid Tumor

NCT02970539 2022-02-16

Ph1b Study of Oraxol in Comb. w. Ramucirumab in Patients w. Gastric, Gastro-esophageal, or Esophageal Cancers

Phase 1 Unknown

36 enrolled

Esophageal Neoplasms, Stomach Neoplasms

NCT00703326 2021-12-06

Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer

1,144 enrolled 19 charts

Breast

Breast Neoplasms

NCT02314117 2021-08-26

RAINFALL

645 enrolled 22 charts

Metastatic Gastric Adenocarcinoma

NCT02564198 2021-08-17

A Study of Ramucirumab (LY3009806) in Children With Refractory Solid Tumors

29 enrolled 12 charts

CNS

Neoplasms, Recurrence, Central Nervous System Neoplasms

NCT02572687 2021-01-20

A Study of Ramucirumab (LY3009806) Plus MEDI4736 in Participants With Advanced Gastrointestinal or Thoracic Malignancies

85 enrolled

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Hepatocellular, Neoplasm Metastasis, Stomach Neoplasms

NCT01246986 2021-01-12

A Study of LY2157299 in Participants With Hepatocellular Carcinoma

Phase 2 Completed

204 enrolled 27 charts

GastrointestinalGenitourinaryThoracic

Carcinoma, Hepatocellular

NCT02082210 2020-12-19

A Study of Emibetuzumab in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer

Phase 1/2 Completed

97 enrolled 20 charts

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Liver Neoplasms

NCT02079636 2020-09-11

A Study of Abemaciclib (LY2835219) in Combination With Another Anti-cancer Drug in Participants With Lung Cancer (NSCLC)

142 enrolled 36 charts

Carcinoma, Non-Small-Cell Lung

NCT02443883 2020-06-29

A Phase 2 Study of Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Junction (GEJ) Cancer

Phase 2 Completed

164 enrolled 13 charts